Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

An NHS doctor has shared that there may be things stopping your cough from going away, but there's a really simple method ...

A cough that produces mucus or phlegm can reveal an underlying infection or condition. Learn about wet cough causes and how ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE: MRK) stands against other stocks that Jim Cramer discussed recently. On Wednesday, Jim Cramer, the host of Mad Money ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.

Eli Lilly's manufacturing plant in Limerick. President Trump said he would shortly unveil tariffs on pharmaceutical imports. (Paulo Nunes dos Santos/Bloomberg News) Stocks in drugmakers sold off ...